在评估超罕见癌症新疗法时的方法学挑战和临床前景
Stefania Bellino1, Anna La Salvia1
1Center for Drug Research and Evaluation, National Institute of Health (Istituto Superiore di Sanità), Rome, Italy.
Current medical research and opinion
|February 21, 2025
概括
开发用于超罕见癌症的治疗方法面临经济和可行性挑战. 创新的临床试验设计和统计方法对于评估个性化医学的新疗法至关重要.
科学领域:
- 在瘤学瘤学.
- 临床试验设计 临床试验设计
- 个性化医疗是个性化的医疗.
背景情况:
- 超罕见的癌症存在重大未满足的医疗需求,传统的药物开发模式往往证明经济上不可行.
- 分子生物学和生物标志物发现的进步正在使个性化医学方法成为可能,包括针对小,分子定义的癌症子集的向治疗.
- 这些疾病的罕见性使标准的临床试验设计复杂化,需要创新的方法.
研究的目的:
- 为突出评估超罕见癌症新疗法所面临的挑战.
- 讨论创新的临床试验设计和统计方法的重要性.
- 为解决这些复杂的疾病的患者管理策略.
主要方法:
- 审查超罕见癌症治疗评估当前的挑战.
- 讨论监管机构指导方针,以灵活规划临床试验.
- 专注于适应性设计,现实世界数据和替代终点.
主要成果:
- 传统的临床试验方法对于超罕见的癌症通常是不可行的.
- 个性化医疗和向疗法看起来有前途,但需要新的评估策略.
- 监管灵活性正在增加,以适应创新的试验设计.
结论:
- 创新的临床试验设计和统计方法对于推进超罕见癌症治疗评估至关重要.
- 调整试验方法以适应罕见疾病特征是开发有效疗法的关键.
- 由于有限的数据和理解,需要专门的患者管理方法.
相关概念视频
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K


